In human medicine, the detection of BRAF mutations in metastatic melanoma patients opened the possibility of BRAF/MAPK-targeted therapy with selective BRAF inhibitors (BRAFi), for instance, vemurafenib or dabrafenib [18]. Here, BRAF is linked to metastatic melanoma.